The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women

Antiviral Therapy

Volumn 16, Issue 2, 2011, Pages 157-164

  Zhang, Jenny ^a   Chung, Ellen ^a   Yones, Cynthia ^a   Persson, Anna ^a   Mahnke, Lisa ^a   Eley, Timothy ^a   Xu, Xiaohui ^a   Bertz, Richard ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; NORELGESTROMIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; METRORRHAGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PATIENT COMPLIANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RASH; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; VOMITING;

ADULT; ANTI-HIV AGENTS; CONTRACEPTIVES, ORAL, COMBINED; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NORGESTREL; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; WOMEN'S HEALTH; YOUNG ADULT;

EID: 79953229201     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1724     Document Type: Article

References (30)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. Department of Health and Human Services (Accessed 10 December 2009.) Available from http://www.aidsinfo. nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
2. UNAIDS, WHO. AIDS epidemic update. December 2007. (Accessed 20 December 2009.) Available from http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate- en.pdf
3. Calderoni ME, Coupey SM. Combined hormonal contraception. Adolesc Med Clin 2005; 16:517-537. (Pubitemid 41393015)
4. Tackett D, Child M, Agarwala S, et al. Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects. 10th Conference on Retroviruses and Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 543.
5. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990; 18:472-484. (Pubitemid 20183889)
6. Shelepova T, Nafziger AN, Victory J, et al. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 2005; 45:1413-1421. (Pubitemid 41642445)
7. Gibaldi M, Perrier D. Pharmacokinetics. New York: Informa Health Care 1982.
8. Ortho Tri-Cyclen (norgestimate/ethinyl estradiol). US prescribing information 2007. Ortho-McNeil-Janssen Pharmaceuticals Inc., Raritan, NJ, USA.
9. Ortho Tri-Cyclen LO (norgestimate/ethinyl estradiol). US prescribing information 2008. Ortho-McNeil-Janssen Pharmaceuticals Inc., Raritan, NJ, USA.
10. Roy P, Jakate AS, Patel A, et al. Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. J Clin Pharmacol 2005; 45:329-336. (Pubitemid 40490429)
11. Golzieher JW. Pharmacokinetics and metabolism of ethinyl estrogens. In Golzieher JW, Fotherby K (Editors). Pharmacology of the contraceptive steroids. New York: Raven Press 1994; pp. 127-151.
12. Orme ML, Back DJ. Factors affecting the enterohepatic circulation of oral contraceptive steroids. Am J Obstet Gynecol 1990; 163:2146-2152.
13. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33:1729-1739.
14. Crixivan (indinavir). US prescribing information 2007. Merck & Co., Inc, Whitehouse Station, NJ, USA.
15. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46:111-116. (Pubitemid 28342780)
16. Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci U S A 2002; 99:13801-13806. (Pubitemid 35215461)
17. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30:795-804. (Pubitemid 34671092)
18. Kaletra (lopinavir/ritonavir). US prescribing information 2007. Abbott Laboratories, Chicago, IL, USA.
19. Faucette SR, Wang H, Hamilton GA, et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004; 32:348-358. (Pubitemid 38263894)
20. Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos 2004; 32:1209-1212. (Pubitemid 39410903)
21. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42:52-60. (Pubitemid 43947946)
22. Rossmanith WG, Steffens D, Schramm G. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. Contraception 1997; 56:23-30. (Pubitemid 27398479)
23. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999; 60:321-329. (Pubitemid 30133220)
24. Poindexter AN, Burkman R, Fisher AC, LaGuardia KD. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO. Int J Fertil Womens Med 2003; 48:163-172.
25. Kasserra C. Effect of vicriviroc with and without ritonavir on oral contraceptive pharmacokinetics. XVII International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract TUBE0043.
26. Kaunitz AM. Enhancing oral contraceptive success: the potential of new formulations. Am J Obstet Gynecol 2004; 190 suppl 4:S23-S29. (Pubitemid 38561490)
27. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109:339-346. (Pubitemid 46197426)
28. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006; 73:566-570.
29. London RS, Chapdelaine A, Upmalis D, Olson W, Smith J. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl 1992; 156:9-14.
30. Reyataz (atazanavir). US prescribing information 2009. Bristol-Myers Squibb, Princeton, NJ, USA.